Tim van Hauwermeiren
Founder at ARGENX SE
Net worth: 36 M $ as of 2024-03-30
Profile
Founder of argenx SE, Tim van Hauwermeiren currently occupies the position of Chairman of Aelin Therapeutics NV and Chief Executive Officer & Executive Director at argenx SE. He is also on the board of iTeos Therapeutics SA and iTeos Therapeutics, Inc. In the past he held the position of Group Head at Procter & Gamble Co. and Senior Manager-Business Development at Ablynx NV. He received an MBA from Vlerick Leuven Gent Management School and a graduate degree and an undergraduate degree from Ghent University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARGEN-X SE
0.12% | 2024-02-19 | 71,986 ( 0.12% ) | 28 M $ | 2024-03-30 |
ARGENX SE ADR
0.03% | 2023-08-30 | 18,100 ( 0.03% ) | 7 M $ | 2024-03-30 |
ITEOS THERAPEUTICS, INC.
-.--% | 2023-06-12 | 0 ( -.--% ) | - $ | 2024-03-30 |
Tim van Hauwermeiren active positions
| Companies | Position | Start |
|---|---|---|
| ARGENX SE | Founder | 2007-12-31 |
| ITEOS THERAPEUTICS, INC. | Director/Board Member | 2018-05-31 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Director/Board Member | 2018-06-26 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Chairman | - |
Former positions of Tim van Hauwermeiren
| Companies | Position | End |
|---|---|---|
| RAYZEBIO, INC. | Director/Board Member | 2024-02-25 |
| ABLYNX | Corporate Officer/Principal | - |
| PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Training of Tim van Hauwermeiren
| Ghent University | Graduate Degree |
| Vlerick Leuven Gent Management School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| ARGENX SE | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
- Stock Market
- Insiders
- Tim van Hauwermeiren
